Objective: To establish the long term outcomes of risk stratified management of differentiated thyroid cancer (DTC).
INTRODUCTION
Differentiated thyroid cancer (DTC) although rare, with a UK annual incidence of 4 per 100,000 population, is the commonest endocrine cancer and the incidence is increasing 1 . The British age-standardised incidence has more than doubled between 1975 and 2008 with a particular increase in small tumours 1 . The reasons for this increase include coincidental detection and increased population awareness -particularly, but not exclusively, for this group of small tumours 2 .
Countries, with the most liberal access to diagnostic imaging and screening, such as the USA and South Korea, have the largest increase in incidence 3,4 .
Although thyroid cancer comprises a heterogeneous range of diseases, including some anaplastic tumours and lymphomas, the majority are indolent. The two main histological types, papillary (PTC) and follicular (FTC) have differences but share an inherently good prognosis and long natural history 5 . Although there is an increase in high quality observational studies there is a virtual absence of randomised trials to properly inform surgical options; thus controversy remains about the optimum treatment for DTC and potential for harms from over-treatment.
There are reports of large case series, some comprising thousands of patients 6 , from tertiary centres with an international referral base and remote long term follow-up 7 , heterogeneous national databases 8 , Far Eastern centres with large numbers and cultural aversion to radiotherapy 9 , with variable primary thyroid and nodal surgery 8 , with relatively short follow-up and proxy outcomes variously managed by radiation oncologists 10 , surgeons or endocrinologists. Furthermore although management related to risk is now being advocated this follows inital radical surgery and radioactive iodine therapy 11 that may represent overtreatment for many patients.The resulting confusion makes formulation of guidelines problematic.
The Grampian region of North East Scotland is geographically remote with a stable population of around 500,000 and a single combined medical/surgical thyroid unit in the Aberdeen Royal Infirmary since the 1950s. The multidisciplinary clinic was the first in the UK to introduce and analyse the impact of Fine Needle Aspiration Cytology (FNAC) on the management of thyroid swellings 12 , 13 and prospectively collected data on thyroid cancer since 1977.
The underlying treatment philosophy was conservative avoiding overtreatment with both surgery and radioactive iodine (RAI). This prospective population based cohort study provides a perspective on the long-term outcome of a simple risk based approach to the management of DTC.
METHODS
This manuscript was prepared to conform to the STROBE statement on cohort observational studies 14 .
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All patients diagnosed with thyroid malignancy in the North East of Scotland between January 1977 and December 2012 were entered in a customised database. Information on preoperative investigation, operative procedure, pathology, adjuvant treatment and follow-up were collected. All patients were routinely consented for inclusion within the database; NHSG R&D did not require separate ethical permission for this analysis. All pathology was reported and reviewed by pathologists with an interest in thyroid cancer on at least three occasions with problematic cases sent elsewhere for further opinions.
Preoperative investigation evolved and included routine thyroid function, autoantibody status and FNAC (post 1981). Chest radiography and CT scanning were used selectively after FNAC or other investigation, e.g. node biopsy indicating DTC. Ultrasound 15 and MRI 16 scanning were evaluated in the 1980s and 90s and abandoned as routine first line investigations. After 2000 ultrasound scans were used to assess lymph nodes in patients scheduled for surgery for nodules confirmed to be, or suspicious for cancer. The minimum investigation necessary to formulate a treatment plan was used.
The surgical strategy until 2000 was to remove all macroscopic disease including involved or suspicious lymph nodes. The majority of patients had a total thyroid lobectomy with bilateral near/total thyroidectomy reserved for patients with bilateral disease, or deemed likely to require RAI. Completion total thyroidectomy following a diagnostic or therapeutic lobectomy was not routine. Post 2000 all patients with a preoperative diagnosis of cancer underwent imaging of the lateral cervical nodes with ultrasound, although some already had CT, MRI and/or latterly PET/CT, to permit directed compartmental nodal dissection. After 2001 diagnostic central compartment node sampling was carried out in patients with no other indication for nodal removal but abandoned with a return to selective surgery after 2010 17 . Limited lateral nodal surgery was defined as removal of macroscopically abnormal lateral lymph nodes within or comprising a single lateral level. lntraoperative nerve monitoring was not used. Adjuvant RAI was based on risk. Whole Body Scanning (WBS) carried out ten days post-administration of theraputic RAI to identify areas of uptake. Low dose RAI diagnostic scans were not used routinely. 
RESULTS
Between January 1977 and December 2012, 348 patients were diagnosed with DTC (Table 2 ). All patients were followed up to the end of 2014, 96.0% in Aberdeen. In terms of primary therapy the majority of patients were treated with lobectomy 189 (54.3%) of 348, which included 30 (33.7%) of 89 AMES high risk patients (Table 3) The results of multivariate analyses are shown in Table 4 . Administration of RAI and AMES high risk were statistically associated with significantly increased risk of DTC death. The risk of recurrence was related to whether the patient had a total thyroidectomy and AMES high risk. MACIS scores were calculated retrospectively for all patients and prospectively for those diagnosed after 2010 and conformed to the risk groups described,
DISCUSSION
This prospective study with long term (mean follow up 14 years) outcomes following treatment of DTC in the UK and is based on a stable population in an isolated geographic region with complete follow-up. There has been a combined medical/surgical thyroid clinic throughout with a commitment to evaluation of process and outcomes in thyroid cancer. We were the first in the UK to introduce and systematically analyse the impact of fine needle aspiration cytology (FNAC) on the management of thyroid swellings. 12,13 Studies of imaging modalities including ultrasound 15 and MRI 16 scanning also influenced the development of efficient local protocols.
Of particular relevance has been a consistently conservative approach to the management of DTC. Although this evolved and became more explicit over the 35 years of patient recruitment, the underlying philosophy was to tailor treatment to risk. Initially the surgical approach was to remove all macroscopic disease with total thyroidectomy reserved for bilateral disease, high risk tumours and adjuvant RAI likely to be required. Following the publication of the first British Association of Endocrine Surgeons guidelines diagnostic central compartment node sampling, with preservation of the thymus where possible and without skeletonisation of the recurrent nerves, was carried out in patients with no clinical or radiological evidence of nodal involvement. We reverted to selective dissection based on clinical assessment at operation after 8 years. 17 Lateral neck dissections became more frequent with levels resected guided by imaging. Frozen section was used intraoperatively to assess questionable nodal involvement. Completion total thyroidectomy was not routine following thyroid lobectomy (Table 3) and TSH was routinely suppressed. Decisions around treatment were made amongst a group comprising surgeons, endocrinologists (responsible for RAI administration) and pathologists until the larger MDT was established in 2000 when ENT surgeons, radiologists and oncologists also contributed. Indications for more radical therapy including RAI and (completion) total thyroidectomy were influenced by adverse pathological features. Follow-up was six monthly for two years then annually thereafter following any surgical procedure. Review comprised examination, measurement of serum TSH, free T3 and T4, and thyroglobulin. Any new symptoms, clinical findings or rise in thyroglobulin triggered further investigation. 18 Elimination of serum thyroglobulin was not a therapeutic objective and a stable (low) serum thyroglobulin was accepted. Patients with serum antithyroglobulin antibodies were managed on an individual basis depending on risk.
Weaknesses of this study include the relatively small population studied, the number of new cancers diagnosed annually and, some will argue, not using ultrasound as a first line investigation. The incidence of DTC in Grampian is the second lowest in Scotland 21 and it can be argued that our practice is missing occult and minimal cancers by not carrying out routine ultrasound, total thyroidectomy and more extensive prophylactic nodal surgery 22 . These criticisms are valid only if such tumours were of clinical significance. The reduction in operation rate in thyroid swellings which followed the introduction of FNAC 12,13 has been sustained over the years with no evidence of late presentation of "missed" cancers 23 . Similarly failure to detect occult disease in the contralateral lobe following lobectomy, in macroscopically normal lymph nodes and distant metastases because prophylactic node dissection and WBS were not used should result in excessively high recurrence rates. This has not happened over the time scale of this study.
Furthermore the cohort of patients managed prior to 1977 and not included in the prospective study has been followed up to death in the same clinic with no evidence to support this hypothesis. Therefore, internal study control negates these possible arguments.
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TSH suppression has conventionally been used to reduce the risk of recurrence, particularly in PTC. Routine complete suppression is associated with potential for adverse cardiovascular outcomes (increased left ventricular mass, tachycardia atrial fibrillation) and osteoporosis 24 and there is now evidence that this is unnecessary in low risk cases 25 . Without a clear contraindication, routine suppression was carried out, and it may be that this practice makes a rise in serum thyroglobulin more meaningful. We do not have data to comment on possible increased cardiac or bone issues related to this policy: it may be timely to review this policy for low risk patients although it will be many years before any change in outcome would be become apparent.
Patients requiring RAI had a WBS ten days post therapy with subsequent doses tailored to uptake, response and thyroglobulin level. Although the proportion of patients receiving RAI increased over time it has remained low compared to most The reliability of the AMES classification in identifying patients at risk of dying of DTC is confirmed beyond doubt (Figure 1c) . It is notable that the cut-off point in terms of size in AMES is 5cm whereas much contemporary debate is around 1-2cm. Two AMES "low risk" patients died: Male, 35 years diagnosed in the 1980's with an 8cm minimal follicular cancer treated by lobectomy presented with cerebral metastatic disease 14 years later which was treated by completion thyroidectomy and RAI but died 15 years after diagnosis: Female, 60 years 3.5cm histologically aggressive papillary cancer treated with total thyroidectomy and RAI but developed early local recurrence and metastases and died 9 years after diagnosis. Both these patients had features which increase perception of risk and the first patient would now also be treated with immediate total thyroidectomy and RAI as was the second.
Whether this would have influenced the outcome is speculative. There is compelling evidence that mortality is related to the biological aggression of the tumour as exhibited in DNA ploidy 28 , 29 regardless of therapy. Although AMES risk was devised to determine mortality it also proved a reliable indicator of the risk of recurrence (Figure 2c ).
Contrary to the influential paper by Mazzaferri 8 thyroid lobectomy was not associated with worse outcomes than total thyroidectomy. In fact the converse was demonstrated (Figure 1a & 2a) . Mazzaferri's paper derived from a heterogeneous national dataset from a mixture of specialist and non-specialist centres and surgeons with no risk stratification recorded or applied. The excellent outcomes in this series following lobectomy alone reflect correct case stratification for low risk of death and, as it transpired, of recurrence. This is entirely consistent with other series reporting a large experience of lobectomy alone for low risk tumours 10,30,31 .
By converse, there is no implication that total thyroidectomy affords an increased risk of poor outcome -simply that biologically aggressive disease was treated maximally, whilst those avoiding maximal treatment came to no harm.
It is very striking that a similar effect is apparent in relation to the use of RAI (Figure 1b & 2b) . Whilst our use of RAI has increased over the years, particularly in patients with TNM Stage III disease (age > 45 years, N1, M0), it remains at a low level and much less than contemporary guidelines and many publications advocate.
There is no evidence from the HiLo trial 32 that routine RAI influences even short term proxy outcomes in low risk cases and we predict the current IoN trial 33 comparing none with low dose RAI in low risk cases will show a similar lack of effect.
We calculated MACIS scores for patients but since this depends on knowledge of the histology of the tumour it was not a useful tool for deciding operative strategy. It is a reliable indicator of long-term risk but as a continuous scale rather than a binary value there is more potential for debate in decision making. Categorical analysis produced similar results to those for TNM staging (Figure 3 ).
14 The overall and TNM stage related outcomes in terms of survival are comparable to all series with similar long-term follow-up despite the conservative treatment policy. The adverse outcomes observed following total thyroidectomy and RAI are not the consequence of more radical surgery or adjuvant RAI but statistical constructs, reflecting that patients at higher risk received more aggressive therapy.
The virtual absence of DTC related death or recurrence in patients deemed at low risk and not undergoing total thyroidectomy or receiving RAI validates the treatment policy based on individual risk. The level of risk is easily estimated from simple parameters known at the time of primary surgery 7 . More extensive thyroid resection and prophylactic nodal dissection may disclose other foci of DTC but the clinical relevance of such incidental disease is inconsequential, consistent with autopsy studies demonstrating population prevalence of over 30% in asymptomatic individuals 34 . Much depends on the confidence of the MDT making these decisions: lack of exposure to the long-term outcomes of a conservative policy and adherence to guidelines with a poverty of evidence leads to over-treatment.
Over-treatment of DTC is increasingly recognised as both financially and clinically detrimental 35 . Medical bankruptcy in the USA is 3.5 times more likely with thyroid than other cancers 36 and many patients could be spared the cost of excessive surgery, RAI and imaging by recognising the benign nature of their DTC. This is particularly relevant in view of the dramatic increase in the rate of diagnosis of low risk DTC cancer over the last two decades 2, 37 . The disadvantages of total thyroidectomy over lobectomy are the doubling of the risk of nerve injury, to both recurrent and superior laryngeal nerves, voice change and hypoparathyroidism.
Although there are many selected series reporting extremely low rates of these complications following routine total thyroidectomy these are not representative of unselected results reported in national registries 38 even amongst high volume surgeons 39 .
Of concern is the potential for long-term effects of therapeutic RAI; apart from acute inflammation in salivary glands due to high uptake. There is a higher rate of malignancy in salivary gland, bowel and bone marrow amongst patients treated with RAI 40 . Whilst this association may be serendipitous the possibility exists that a second potentially more lethal malignancy may be induced by a high dose of radiation administered unnecessarily for a tumour with a negligible risk of death. This is especially relevant when the patient is young. Even if the second malignancy is not caused by RAI there is a cogent argument for avoiding unnecessary irradiation to patients with an apparent increased predisposition to develop cancer compared to the normal population.
Elimination of serum thyroglobulin as a therapeutic objective and proxy for long-term survival is problematic for a number of reasons. In many centres detectable thyroglobulin is considered to represent recurrence and Increasingly sensitive assays lower the threshold for such detection, When this initiates a search for recurrence occult disease may be found or suspected with the potential for further, more risky surgery and which may not impact on survival or clinically relevant recurrence. Only one third of tissue resected for such 'recurrence' is subsequently histologically confirmed 41 -the concept of overtreatment may apply beyond that of the primary intervention.
The uncertainty around recommendations for optimal management for low risk cancers remains manifest in guidelines; the 2014 British Thyroid Association guidelines state " The evidence for an advantage of total thyroidectomy compared to hemithyroidectomy in patients with unifocal tumours >1-≤4 cm in diameter, age <45 years, with no extrathyroidal spread, no familial disease, no evidence of lymph node involvement, no angioinvasion and no distant metastases, is unclear" 42 . This study clarifies the position. The AMES criteria for defining risk may appear liberal to practitioners accustomed to a policy of total thyroidectomy and RAI for all but are justified not only in terms of mortality but also, and previously unreported, recurrence. The debate on the optimal management of DTC will continue but the movement away from routine aggressive multimodal therapy for all DTC manifest in early guidelines is already clear 43 and will continue. In practical terms no patient with papillary thyroid cancer selected to receive only thyroid lobectomy and no RAI died of thyroid cancer. Simple clinical risk stratification based on information available at the time of the primary surgery avoided the cost and complications of overtreatment in many patients with no demonstrable detriment over 37 years of this study. Radical surgery and adjuvant RAI therapy based on the risk of death and recurrence can be restricted to those at higher risk with the proviso that neither of these major outcomes may be affected in those with the most aggressive cancers. +ve: malignancy present in second lobectomy specimen Table   Table 4 Disease specific survival 
